Zenivol achieves major milestone with formal regulatory approval received in Germany

Jul 13, 2022

Zelira Therapeutics Limited (ASX: ZLD) announced that it had received formal approval from the German regulatory authority BfArM through its German commercialization partner Adjupharm GmbH. This approval will help the company to enter into Germany, which is one of the largest market in the world for cannabinoid-based medicines and Europe’s largest market, through its 5-year exclusive distribution agreement with Adjupharm. The approval will also expand the availability of Zenivol beyond Australia for the first time.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au